Guilherme Nader Marta, Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Biomarker analyses of KN-522 shows most markers (T-cell GEP, HRD, HER2 signaling, PTEN, TNBC type) were prognostic but not predictive.
High TMB showed a signal for pembro benefit, but only in 8% of patients.
Predictive biomarkers for ICI in early TNBC are urgently needed.”
More posts featuring Guilherme Nader Marta.